Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 16, 2023 08:32 ET | Source: The Insight Partners

Radioactive Tracer Market Worth $54.29 Billion by 2030 - Exclusive Report by The Insight Partners

Pune, India, Aug. 16, 2023 (GLOBE NEWSWIRE) -- A radioactive tracer is a chemical compound in which one or more atoms have been replaced by a radioisotope. Through monitoring its radioactive decay,...
August 15, 2023 10:50 ET | Source: Curium

Curium Announces Achievement of Co-Primary Endpoints in Phase 2 of Its Phase 1/2 SOLAR Clinical Trial Imaging Men With Histologically-Proven Prostate Cancer Using Copper Cu 64 PSMA I&T

PARIS, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the positive results of the multi-center, open-label, Phase 2 SOLAR study of Copper Cu 64 PSMA...
July 28, 2023 06:12 ET | Source: Curium

Curium Receives Marketing Authorization in the EU for PYLCLARI™, an Innovative 18F-PSMA PET Tracer Indicated in Adults With Prostate Cancer

PARIS, July 28, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that the European Commission has granted marketing authorization for PYLCLARI™ (INN: Piflufolastat...
July 25, 2023 06:06 ET | Source: Curium

Curium Announces License and Development Agreement With Lantheus for AI-Based PSMA PET Software in Europe

Builds on existing collaboration between Curium and Lantheus for prostate cancer PSMA-targeted PET imagingDeep-learning platform for standardization of comprehensive reporting in Europe PARIS, July ...
March 14, 2023 10:46 ET | Source: Curium

Curium Confirms No Supply Challenges in North America and Europe for its Eclipse Phase 3 Clinical Trial

To date, an uninterrupted supply of 177Lu-PSMA-I&TRobust supply chains and global transportation infrastructure deliver supply securityCurium’s clinical trials play central role in innovations in...
January 26, 2022 16:51 ET | Source: Telix Pharmaceuticals Limited

First Patient Dosed in ProstACT Program for Prostate Cancer Therapy

MELBOURNE, Australia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s...
November 14, 2021 15:59 ET | Source: Telix Pharmaceuticals Limited

NOBLE Study Brings Advanced Prostate Imaging to Rural Australia – First Patient Dosed

MELBOURNE, Australia, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first Australian patient has been dosed in the...
April 20, 2021 10:32 ET | Source: Telix Pharmaceuticals Limited

The NOBLE Registry – An International Collaboration to Develop iPSMA SPECT Imaging for Prostate Cancer

BRUSSELS, Belgium and MELBOURNE, Australia, April 20, 2021 (GLOBE NEWSWIRE) -- The Oncidium Foundation, a non-profit organisation created to promote and support the development of...
March 30, 2021 18:02 ET | Source: Telix Pharmaceuticals Limited

Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®

MELBOURNE, Australia and INDIANAPOLIS, March 30, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that it has completed an agreement with...
February 16, 2021 01:05 ET | Source: Telix Pharmaceuticals Limited

Czech Republic First European Country to Grant National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product

MELBOURNE, Australia and LIÈGE, Belgium, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that the Ministry of Health of the...